SCLP Scancell Holdings Plc

17 February 2025

Scancell Holdings plc

("Scancell" or the "Company")

Scancell to present translational data from the Phase 2 ongoing SCOPE trial of SCIB1 at the 2025 AACR IO conference

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapy products for the treatment of multiple cancers, announce translational data from the SCOPE trial demonstrating SCIB1 combined with nivolumab and ipilimumab  will be presented during a poster session at the AACR IO conference, taking place in Los Angeles, California on 23-26 February 2025.

SCIB1, a DNA plasmid melanoma cancer vaccine, is the lead product from the Company's ImmunoBody® DNA Vaccine platform, which uses the body's immune system to identify, attack and destroy tumours. The SCOPE Study (NCT04079166) is a Phase 2, Multicentre Open-Label, Study, investigating SCIB1 with double checkpoint inhibitors ("CPIs") in late-stage melanoma. So far, 25 patients in cohort 1, receiving SCIB1 in combination with ipilimumab and nivolumab, have shown 84% disease control rate, 80% progression free survival and 20% complete response rate. The translational data that will be presented demonstrates functional vaccine specific T cell responses for patients enrolled in cohort 1 (SCIB1 plus ipilimumab and nivolumab).

Phil L'Huillier, Chief Executive Officer, Scancell, commented: "Presenting data showing vaccine specific T cell responses at AACR IO is an important validation of SCIB1 efficacy in advanced melanoma. This data supports the latest findings from the Phase 2 Scope trial, evaluating SCIB1 in combination with CPIs. We look forward to sharing the latest insights with leading industry experts at AACR IO."

Poster presentation details are as follows:

Title: A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab induces functional CD4 and CD8 T cell responses in patients with advanced unresectable melanoma.

Poster no.: B119

Session type: Poster session B

Session date and time: 25 February 2025, 13:45-16:45 PT

Location: Platinum Ballroom A-J

Speaker: Joseph Chadwick

Authors: Joseph Chadwick, Gaëlle Cane, Sabaria Shah, Katie Mann, Patrick Copeland, Daisy Weston, Jordan Wright, Leanne Toon, Heather Shaw, Poulam Patel, Miranda Payne, Satish Kumar, Sarah Danson, Martin Highley, Clare Barlow, Kellati Prasad, Ioannis Karydis, Maria Marples, Kate Young, Pippa Corrie, Robert Miller, Rachael Metheringham, Georgia Goodhew, Nermeen Varawalla, Samantha Paston and Lindy Durrant.

If you would like to arrange a meeting at the conference, please contact commercial.enquiries@scancell.co.uk.

About SCIB1/iSCIB1+ 

SCIB1 is the lead product from the Company's ImmunoBody® DNA Vaccine platform, which uses the body's immune system to identify, attack and destroy tumours. iSCIB1+ is a modified version of SCIB1 developed using Scancell's AvidiMab® platform to enhance its potency compared to SCIB1. iSCIB1+ also includes additional melanoma-specific epitopes so it has the potential to be effective in a broader patient population beyond the 40% of patients with the tissue type treatable with SCIB1, where treatment is human leukocyte antigen (HLA) dependent.  

About the SCOPE Study 

The SCOPE Study (NCT04079166) is a Phase 2, Multicentre, Open-Label, Umbrella Study of SCIB1 and iSCIB1+ in Patients With Advanced Unresectable Melanoma Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab to determine the response rate and safety and tolerability of intramuscular SCIB1 or iSCIB1+ when added to nivolumab (Opdivo) with ipilimumab (Yervoy) or SCIB1 with pembrolizumab (Keytruda). Conducted across approximately 15 sites in the United Kingdom, this multi-site trial aims to demonstrate durable and potent anti-tumour activity and ORR of SCIB1/Iscib1+ in addition to standard of care checkpoint inhibitors. Additional endpoints include duration of response (DOR), progression free survival (PFS), overall survival (OS), safety, and tolerability. Participants receive up to 10 doses of either SCIB1 or iSCIB1+ using PharmaJet Stratis® needle-free injection device system in the upper arm or upper leg. up to 85 weeks, in combination with nivolumab with ipilimumab or SCIB1 with pembrolizumab. More information on this trial can be found at clinicaltrials.gov or www.clinicaltrialsregister.eu. 

About Scancell 

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies.  Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope® and ImmunoBody® ) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab® ) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab® ).  

For further information about Scancell, please visit: https://www.scancell.co.uk/